◆

Subtypes

4

Kleefstra syndrome 1 MONDO:0027407

Caused by haploinsufficiency of EHMT1, either through microdeletion or intragenic mutation. Accounts for the majority of Kleefstra syndrome cases.

Kleefstra syndrome due to 9q34 microdeletion
Kleefstra syndrome due to a point mutation

Kleefstra syndrome due to 9q34 microdeletion MONDO:0019896

Caused by heterozygous microdeletion at 9q34.3 encompassing EHMT1. Accounts for approximately 50% of EHMT1-related cases. Deletion size varies from ~0.2 Mb to >3 Mb; larger deletions may include additional genes contributing to phenotypic variability.

Kleefstra syndrome due to a point mutation MONDO:0016865

Caused by intragenic loss-of-function mutations in EHMT1, including nonsense, frameshift, and splice-site variants. Accounts for approximately 50% of EHMT1-related cases. The phenotype is generally similar to the deletion subtype.

Kleefstra syndrome 2 MONDO:0054701

Caused by heterozygous loss-of-function mutations in KMT2C (MLL3), a histone H3 lysine 4 methyltransferase. Phenotypically overlaps with Kleefstra syndrome 1 but involves a distinct chromatin-modifying gene.

⚙

Pathophysiology

3

EHMT1 haploinsufficiency and epigenetic dysregulation

EHMT1 (also known as GLP) encodes a SET domain-containing histone methyltransferase that forms a heterodimeric complex with EHMT2 (G9a). This complex catalyzes mono- and dimethylation of histone H3 at lysine 9 (H3K9me1/me2), an epigenetic mark associated with transcriptional silencing at euchromatic loci. Haploinsufficiency of EHMT1 leads to reduced H3K9me2 levels, resulting in aberrant gene expression across multiple tissues, particularly in the developing brain. The minimal critical region for the syndrome has been narrowed to less than 1 Mb comprising EHMT1.

neuron link

peptidyl-lysine methylation link ↓ DECREASED chromatin organization link ↕ DYSREGULATED

Downstream

NMDAR-mediated neuronal network dysfunction Reduced H3K9me2 at the GRIN1 promoter leads to upregulation of NMDA receptor subunit 1 and aberrant neuronal network activity.

REST/NRSF dysregulation via miRNA derepression EHMT1 deficiency derepresses miRNAs that target REST/NRSF, reducing REST protein and prematurely activating neuronal gene programs.

Show evidence (2 references)

PMID:16826528 SUPPORT Human Clinical

"haploinsufficiency for EHMT1 is causative for 9q subtelomeric deletion syndrome"

Original identification of EHMT1 loss-of-function mutations as the cause of the 9q34 subtelomeric deletion syndrome (now Kleefstra syndrome).

DOI:10.1038/s41467-019-12947-3 SUPPORT In Vitro

"these changes are mediated by upregulation of NMDA receptor (NMDAR) subunit 1 correlating with reduced deposition of the repressive H3K9me2 mark, the catalytic product of EHMT1, at the GRIN1 promoter"

iPSC-derived cortical neurons from KS patients show reduced H3K9me2 at the GRIN1 promoter, directly linking EHMT1 haploinsufficiency to specific gene derepression.

NMDAR-mediated neuronal network dysfunction

In EHMT1-deficient human cortical neurons, reduced H3K9me2 at the GRIN1 promoter leads to upregulation of NMDA receptor subunit 1 (NMDAR1/GluN1), driving aberrant neuronal network activity with reduced burst rate, longer burst duration, and increased temporal irregularity. Pharmacological inhibition of NMDARs rescues the network phenotype, establishing a direct mechanistic link between EHMT1 deficiency and NMDAR hyperfunction that provides a potential basis for targeted therapeutic approaches.

excitatory cortical neuron link

regulation of synaptic plasticity link ↕ DYSREGULATED

cerebral cortex link

Downstream

Intellectual disability and speech delay Disrupted neuronal network dynamics and synaptic plasticity underlie cognitive impairment and language deficits.

Seizures Imbalanced excitatory neurotransmission through NMDAR hyperfunction contributes to epileptogenesis.

Show evidence (2 references)

DOI:10.1038/s41467-019-12947-3 SUPPORT In Vitro

"Neuronal networks of patient-derived cells exhibit network bursting with a reduced rate, longer duration, and increased temporal irregularity compared to control networks"

iPSC-derived excitatory cortical neuron networks from KS patients show characteristic network dysfunction that is rescued by NMDAR antagonism.

DOI:10.1038/s41467-019-12947-3 SUPPORT In Vitro

"we rescue the KS patient-derived neuronal network phenotypes by pharmacological inhibition of NMDARs"

Pharmacological rescue with NMDAR antagonists demonstrates that NMDAR hyperfunction is a key driver of network dysfunction in KS.

REST/NRSF dysregulation via miRNA derepression

EHMT1 deficiency leads to derepression of multiple miRNAs that target the neuronal transcriptional repressor REST/NRSF. EHMT1 normally maintains H3K9me2 marks at miRNA transcription start sites, keeping them silenced. When EHMT1 is haploinsufficient, these miRNAs are upregulated, reducing REST protein levels and prematurely de-repressing neuronal gene programs. This disrupts the timing of neurodevelopment and contributes to the aberrant neuronal differentiation seen in Kleefstra syndrome.

neuron link

neuron differentiation link ⚠ ABNORMAL

Show evidence (2 references)

DOI:10.1038/s41398-022-02199-z SUPPORT In Vitro

"reduced EHMT1 activity decreases NRSF/REST protein leading to abnormal neuronal gene expression and progression of neurodevelopment in human iPSC"

Human iPSC model shows EHMT1 deficiency reduces REST protein via miRNA-mediated mechanisms, causing premature neuronal gene activation.

DOI:10.1038/s41398-022-02199-z SUPPORT In Vitro

"EHMT1 regulates NRSF/REST indirectly via repression of miRNA and leads to aberrant neuronal gene regulation and neurodevelopment timing"

Establishes the indirect EHMT1-miRNA-REST pathway as a mechanism for altered neurodevelopmental timing in Kleefstra syndrome.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

Referential integrity issues (1):

Target 'Intellectual disability and speech delay' (from 'NMDAR-mediated neuronal network dysfunction') not found in named elements

●

Phenotypes

13

Cardiovascular 1

Congenital heart defects FREQUENT Abnormal heart morphology (HP:0001627)

Show evidence (1 reference)

PMID:39746677 SUPPORT Human Clinical

"Systemic health issues included structural cardiac defects (40%), hearing loss (32%), and constipation (31%)."

Large clinical cohort (n=65) found structural cardiac defects in 40% of individuals with Kleefstra syndrome.

Eye 1

Hypertelorism Hypertelorism (HP:0000316)

Show evidence (1 reference)

PMID:16826528 SUPPORT Human Clinical

"flat face with hypertelorism, synophrys, anteverted nares"

Hypertelorism is listed among the core craniofacial features.

Head and Neck 2

Distinctive facial features Flat face (HP:0012368)

Show evidence (1 reference)

PMID:16826528 SUPPORT Human Clinical

"brachycephaly, flat face with hypertelorism, synophrys, anteverted nares, cupid bow or tented upper lip, everted lower lip, prognathism, macroglossia"

The original characterization provides the full description of the distinctive facial phenotype.

Brachycephaly Brachycephaly (HP:0000248)

Show evidence (1 reference)

PMID:16826528 SUPPORT Human Clinical

"brachycephaly, flat face with hypertelorism"

Brachycephaly is listed as a core craniofacial feature in the original syndrome description.

Musculoskeletal 1

Childhood hypotonia VERY_FREQUENT Hypotonia (HP:0001252)

Show evidence (1 reference)

PMID:16826528 SUPPORT Human Clinical

"severe mental retardation, hypotonia, brachycephaly, flat face with hypertelorism"

Original description of the 9q34 subtelomeric deletion syndrome identifies hypotonia as a cardinal feature.

Nervous System 7

Intellectual disability VERY_FREQUENT Intellectual disability (HP:0001249)

Show evidence (1 reference)

DOI:10.1136/jmg-2023-109702 SUPPORT Human Clinical

"The cognitive spectrum ranged from average intelligence (12/79, 15%) to severe intellectual disability (12/79, 15%)"

Large cohort study (n=103) establishes the cognitive spectrum in KS, showing most but not all individuals have intellectual disability.

Severe speech and language impairment VERY_FREQUENT Delayed speech and language development (HP:0000750)

Show evidence (2 references)

DOI:10.1136/jmg-2023-109702 SUPPORT Human Clinical

"Speech disorders occurred in 48/49 (98%) verbal individuals and even occurred alongside average language and cognition"

Near-universal speech disorder in verbal KS individuals, with dysarthria and childhood apraxia of speech as predominant types.

DOI:10.1136/jmg-2023-109702 SUPPORT Human Clinical

"Language ability also ranged from average (10/90, 11%) to severely impaired (53/90, 59%)"

Demonstrates the broad language spectrum with majority showing severe impairment.

Global developmental delay VERY_FREQUENT Global developmental delay (HP:0001263)

Show evidence (1 reference)

PMID:16826528 SUPPORT Human Clinical

"severe mental retardation, hypotonia, brachycephaly, flat face with hypertelorism"

The original characterization of the syndrome includes severe developmental delay as a defining feature.

Seizures OCCASIONAL Seizure (HP:0001250)

Epilepsy affected 15% of a large clinical cohort (Frazier et al. 2025, PMID:39746677). No specific snippet available for the seizure phenotype.

Developmental regression OCCASIONAL Developmental regression (HP:0002376)

Show evidence (1 reference)

DOI:10.1136/jmg-2023-109702 SUPPORT Human Clinical

"Developmental regression occurred in 11/80 (14%) individuals across motor, language and psychosocial domains"

Regression is a recognized but minority feature, across multiple developmental domains.

Autistic behavior FREQUENT Autistic behavior (HP:0000729)

Show evidence (1 reference)

PMID:39746677 SUPPORT Human Clinical

"Behavioral disorders, such as autism spectrum disorder (38%), were common."

Large clinical cohort (n=65) at Boston Children's Hospital Kleefstra Clinic found ASD in 38% of individuals, directly supporting autistic behavior as a frequent phenotype.

Sleep disturbances FREQUENT Sleep disturbance (HP:0002360)

Sleep disturbance frequency (63%) based on Morison et al. 2024 cohort of 103 individuals.

Growth 1

Obesity FREQUENT Obesity (HP:0001513)

Childhood-onset obesity is a recognized feature but no specific prevalence data with quotable abstract snippet is available.

🧬

Genetic Associations

3

EHMT1 haploinsufficiency (9q34.3 deletion) (Causative)

Autosomal dominant inheritance

Show evidence (3 references)

PMID:16826528 SUPPORT Human Clinical

"The minimal critical region responsible for this 9q subtelomeric deletion (9q-) syndrome has been estimated to be <1 Mb and comprises the euchromatin histone methyl transferase 1 gene (EHMT1)"

Establishes that the minimal critical deletion region includes EHMT1 and is less than 1 Mb.

PMID:16826528 SUPPORT Human Clinical

"we identified two de novo mutations--a nonsense mutation and a frameshift mutation--in the EHMT1 gene in patients with a typical 9q- phenotype"

Demonstrates that intragenic EHMT1 mutations cause the same phenotype as deletions, proving EHMT1 haploinsufficiency is causative.

CGGV:assertion_db91a861-6a88-4848-b6d5-4772bdef52ff-2018-06-06T100000.000Z SUPPORT Other

ClinGen classifies the EHMT1-Kleefstra syndrome gene-disease relationship as definitive with autosomal dominant inheritance.

EHMT1 intragenic pathogenic variants (Causative)

Autosomal dominant inheritance

Show evidence (1 reference)

PMID:16826528 SUPPORT Human Clinical

"These results establish that haploinsufficiency of EHMT1 is causative for 9q subtelomeric deletion syndrome"

Original paper proving EHMT1 intragenic mutations cause the syndrome.

KMT2C loss-of-function variants (Causative)

Autosomal dominant inheritance

💊

Treatments

4

Speech and Language Therapy

Action: speech therapy MAXO:0000930

Speech therapy is utilized by 97% of individuals in the largest cohort (100/103). Communication aids such as sign language and speech-generating devices are crucial for 59% of individuals.

Show evidence (1 reference)

DOI:10.1136/jmg-2023-109702 SUPPORT Human Clinical

"Communication aids, such as sign and speech-generating devices, were crucial for 61/103 (59%) individuals including those who were minimally verbal, had a speech disorder or following regression"

High utilization of speech therapy and communication aids demonstrates centrality of speech/language intervention in KS management.

Early Intervention and Rehabilitation

Action: early intervention services MAXO:0009101

Early developmental intervention is the cornerstone of management. Occupational therapy (86%), physiotherapy (89%), and speech therapy (97%) are utilized by the vast majority of individuals.

Show evidence (1 reference)

DOI:10.1136/jmg-2023-109702 SUPPORT Human Clinical

"Early access to communication aids may improve communication and quality of life"

Evidence supports early intervention for improved communication outcomes in KS.

Antiepileptic Drug Therapy

Action: antiepileptic drug therapy Ontology label: anticonvulsant agent therapy MAXO:0000167

Standard antiepileptic medications are used to manage seizures in the approximately 12% of patients who develop epilepsy. Seizure type guides drug selection.

Behavioral Management

Action: supportive care MAXO:0000950

Behavioral interventions for autism spectrum features, sleep disturbances, and challenging behaviors. May include applied behavior analysis and structured behavioral support.

{ }

Source YAML

click to show

name: Kleefstra Syndrome
creation_date: "2026-03-20T00:15:00Z"
updated_date: "2026-04-22T20:13:21Z"
category: Mendelian
synonyms:
- 9q34 deletion syndrome
- 9q34.3 microdeletion syndrome
- 9q subtelomeric deletion syndrome
description: >
  Kleefstra syndrome is a rare neurodevelopmental disorder caused by haploinsufficiency
  of the EHMT1 gene (euchromatic histone lysine methyltransferase 1) at chromosome
  9q34.3. It occurs either through heterozygous microdeletions encompassing EHMT1
  or through intragenic loss-of-function mutations. EHMT1 encodes a histone
  methyltransferase that catalyzes mono- and dimethylation of histone H3 at lysine 9
  (H3K9me1/me2), a key epigenetic mark for transcriptional repression and
  heterochromatin formation. The syndrome is characterized by intellectual disability,
  childhood hypotonia, severe expressive speech delay, and distinctive facial features
  including brachycephaly, midface hypoplasia, and hypertelorism. Additional features
  may include autism spectrum behavior, seizures, congenital heart defects, obesity,
  and sleep disturbances.
disease_term:
  preferred_term: Kleefstra syndrome
  term:
    id: MONDO:0012455
    label: Kleefstra syndrome
has_subtypes:
- name: Kleefstra syndrome 1
  subtype_term:
    preferred_term: Kleefstra syndrome 1
    term:
      id: MONDO:0027407
      label: Kleefstra syndrome 1
  description: >
    Caused by haploinsufficiency of EHMT1, either through microdeletion
    or intragenic mutation. Accounts for the majority of Kleefstra syndrome cases.
  children:
  - Kleefstra syndrome due to 9q34 microdeletion
  - Kleefstra syndrome due to a point mutation
- name: Kleefstra syndrome due to 9q34 microdeletion
  subtype_term:
    preferred_term: Kleefstra syndrome due to 9q34 microdeletion
    term:
      id: MONDO:0019896
      label: Kleefstra syndrome due to 9q34 microdeletion
  description: >
    Caused by heterozygous microdeletion at 9q34.3 encompassing EHMT1.
    Accounts for approximately 50% of EHMT1-related cases. Deletion
    size varies from ~0.2 Mb to >3 Mb; larger deletions may include additional
    genes contributing to phenotypic variability.
- name: Kleefstra syndrome due to a point mutation
  subtype_term:
    preferred_term: Kleefstra syndrome due to a point mutation
    term:
      id: MONDO:0016865
      label: Kleefstra syndrome due to a point mutation
  description: >
    Caused by intragenic loss-of-function mutations in EHMT1, including
    nonsense, frameshift, and splice-site variants. Accounts for approximately
    50% of EHMT1-related cases. The phenotype is generally similar to the
    deletion subtype.
- name: Kleefstra syndrome 2
  subtype_term:
    preferred_term: Kleefstra syndrome 2
    term:
      id: MONDO:0054701
      label: Kleefstra syndrome 2
  description: >
    Caused by heterozygous loss-of-function mutations in KMT2C (MLL3),
    a histone H3 lysine 4 methyltransferase. Phenotypically overlaps with
    Kleefstra syndrome 1 but involves a distinct chromatin-modifying gene.
parents:
- Neurodevelopmental disorder
- Chromosomal microdeletion syndrome
- Epigenetic disorder
prevalence:
- population: Global reported literature and intellectual disability cohorts
  percentage: Unknown (estimated 1 in 200,000 among cases with intellectual disability)
  notes: >-
    No population-based prevalence study was identified. A recent review abstract
    states that Kleefstra syndrome has an estimated frequency of 1 in 200,000
    among cases with intellectual disability and notes that approximately 110
    patients had been reported in the literature at that time.
  evidence:
  - reference: PMID:35633020
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The true prevalence of KS is unknown, but it is estimated that it occurs
      with a frequency of 1/200.000 in cases with mental retardation. On
      literature search, approximately 110 patients have been reported so far.
    explanation: >-
      This review abstract provides the clearest explicit prevalence statement
      found for Kleefstra syndrome and also shows that published case counts
      remained limited.
pathophysiology:
- name: EHMT1 haploinsufficiency and epigenetic dysregulation
  description: >
    EHMT1 (also known as GLP) encodes a SET domain-containing histone
    methyltransferase that forms a heterodimeric complex with EHMT2 (G9a).
    This complex catalyzes mono- and dimethylation of histone H3 at lysine 9
    (H3K9me1/me2), an epigenetic mark associated with transcriptional silencing
    at euchromatic loci. Haploinsufficiency of EHMT1 leads to reduced H3K9me2
    levels, resulting in aberrant gene expression across multiple tissues,
    particularly in the developing brain. The minimal critical region for the
    syndrome has been narrowed to less than 1 Mb comprising EHMT1.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: peptidyl-lysine methylation
    term:
      id: GO:0018022
      label: peptidyl-lysine methylation
    modifier: DECREASED
  - preferred_term: chromatin organization
    term:
      id: GO:0006325
      label: chromatin organization
    modifier: DYSREGULATED
  downstream:
  - target: NMDAR-mediated neuronal network dysfunction
    description: >
      Reduced H3K9me2 at the GRIN1 promoter leads to upregulation of NMDA
      receptor subunit 1 and aberrant neuronal network activity.
  - target: REST/NRSF dysregulation via miRNA derepression
    description: >
      EHMT1 deficiency derepresses miRNAs that target REST/NRSF, reducing
      REST protein and prematurely activating neuronal gene programs.
  evidence:
  - reference: PMID:16826528
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "haploinsufficiency for EHMT1 is causative for 9q subtelomeric deletion syndrome"
    explanation: >
      Original identification of EHMT1 loss-of-function mutations as the cause
      of the 9q34 subtelomeric deletion syndrome (now Kleefstra syndrome).
  - reference: DOI:10.1038/s41467-019-12947-3
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "these changes are mediated by upregulation of NMDA receptor (NMDAR) subunit 1 correlating with reduced deposition of the repressive H3K9me2 mark, the catalytic product of EHMT1, at the GRIN1 promoter"
    explanation: >
      iPSC-derived cortical neurons from KS patients show reduced H3K9me2 at
      the GRIN1 promoter, directly linking EHMT1 haploinsufficiency to
      specific gene derepression.
- name: NMDAR-mediated neuronal network dysfunction
  description: >
    In EHMT1-deficient human cortical neurons, reduced H3K9me2 at the GRIN1
    promoter leads to upregulation of NMDA receptor subunit 1 (NMDAR1/GluN1),
    driving aberrant neuronal network activity with reduced burst rate, longer
    burst duration, and increased temporal irregularity. Pharmacological
    inhibition of NMDARs rescues the network phenotype, establishing a direct
    mechanistic link between EHMT1 deficiency and NMDAR hyperfunction that
    provides a potential basis for targeted therapeutic approaches.
  cell_types:
  - preferred_term: excitatory cortical neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: regulation of synaptic plasticity
    term:
      id: GO:0048167
      label: regulation of synaptic plasticity
    modifier: DYSREGULATED
  locations:
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  downstream:
  - target: Intellectual disability and speech delay
    description: >
      Disrupted neuronal network dynamics and synaptic plasticity underlie
      cognitive impairment and language deficits.
  - target: Seizures
    description: >
      Imbalanced excitatory neurotransmission through NMDAR hyperfunction
      contributes to epileptogenesis.
  evidence:
  - reference: DOI:10.1038/s41467-019-12947-3
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Neuronal networks of patient-derived cells exhibit network bursting with a reduced rate, longer duration, and increased temporal irregularity compared to control networks"
    explanation: >
      iPSC-derived excitatory cortical neuron networks from KS patients show
      characteristic network dysfunction that is rescued by NMDAR antagonism.
  - reference: DOI:10.1038/s41467-019-12947-3
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "we rescue the KS patient-derived neuronal network phenotypes by pharmacological inhibition of NMDARs"
    explanation: >
      Pharmacological rescue with NMDAR antagonists demonstrates that NMDAR
      hyperfunction is a key driver of network dysfunction in KS.
- name: REST/NRSF dysregulation via miRNA derepression
  description: >
    EHMT1 deficiency leads to derepression of multiple miRNAs that target the
    neuronal transcriptional repressor REST/NRSF. EHMT1 normally maintains
    H3K9me2 marks at miRNA transcription start sites, keeping them silenced.
    When EHMT1 is haploinsufficient, these miRNAs are upregulated, reducing
    REST protein levels and prematurely de-repressing neuronal gene programs.
    This disrupts the timing of neurodevelopment and contributes to the
    aberrant neuronal differentiation seen in Kleefstra syndrome.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: neuron differentiation
    term:
      id: GO:0030182
      label: neuron differentiation
    modifier: ABNORMAL
  evidence:
  - reference: DOI:10.1038/s41398-022-02199-z
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "reduced EHMT1 activity decreases NRSF/REST protein leading to abnormal neuronal gene expression and progression of neurodevelopment in human iPSC"
    explanation: >
      Human iPSC model shows EHMT1 deficiency reduces REST protein via
      miRNA-mediated mechanisms, causing premature neuronal gene activation.
  - reference: DOI:10.1038/s41398-022-02199-z
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "EHMT1 regulates NRSF/REST indirectly via repression of miRNA and leads to aberrant neuronal gene regulation and neurodevelopment timing"
    explanation: >
      Establishes the indirect EHMT1-miRNA-REST pathway as a mechanism for
      altered neurodevelopmental timing in Kleefstra syndrome.
phenotypes:
- category: Neurological
  name: Intellectual disability
  frequency: VERY_FREQUENT
  description: >
    Intellectual disability is a core feature, with a broad cognitive spectrum.
    In a cohort of 103 individuals, 85% had intellectual disability (mild 20%,
    moderate 48%, severe 15%), while 15% had average cognitive ability.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: DOI:10.1136/jmg-2023-109702
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The cognitive spectrum ranged from average intelligence (12/79, 15%) to severe intellectual disability (12/79, 15%)"
    explanation: >
      Large cohort study (n=103) establishes the cognitive spectrum in KS,
      showing most but not all individuals have intellectual disability.
- category: Neurological
  name: Childhood hypotonia
  frequency: VERY_FREQUENT
  description: >
    Muscular hypotonia is typically present from infancy and contributes to delayed
    motor milestones. It tends to improve with age but may persist.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:16826528
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "severe mental retardation, hypotonia, brachycephaly, flat face with hypertelorism"
    explanation: >
      Original description of the 9q34 subtelomeric deletion syndrome
      identifies hypotonia as a cardinal feature.
- category: Neurological
  name: Severe speech and language impairment
  frequency: VERY_FREQUENT
  description: >
    Speech and language development is severely affected. In a cohort of 103
    individuals, 59% had severe language impairment, and 98% of verbal
    individuals had a speech disorder, including dysarthria (69%) and childhood
    apraxia of speech (59%). Communication aids were used by 59% of individuals.
  phenotype_term:
    preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: DOI:10.1136/jmg-2023-109702
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Speech disorders occurred in 48/49 (98%) verbal individuals and even occurred alongside average language and cognition"
    explanation: >
      Near-universal speech disorder in verbal KS individuals, with dysarthria
      and childhood apraxia of speech as predominant types.
  - reference: DOI:10.1136/jmg-2023-109702
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Language ability also ranged from average (10/90, 11%) to severely impaired (53/90, 59%)"
    explanation: >
      Demonstrates the broad language spectrum with majority showing
      severe impairment.
- category: Neurological
  name: Global developmental delay
  frequency: VERY_FREQUENT
  description: >
    Significant delay in achieving developmental milestones including motor,
    cognitive, and language domains, typically apparent within the first year
    of life.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:16826528
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "severe mental retardation, hypotonia, brachycephaly, flat face with hypertelorism"
    explanation: >
      The original characterization of the syndrome includes severe
      developmental delay as a defining feature.
- category: Neurological
  name: Seizures
  frequency: OCCASIONAL
  description: >
    Epilepsy occurs in a minority of patients. Seizure types are variable
    and onset is typically in childhood.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  notes: >
    Epilepsy affected 15% of a large clinical cohort (Frazier et al. 2025,
    PMID:39746677). No specific snippet available for the seizure phenotype.
  evidence: []
- category: Neurological
  name: Developmental regression
  frequency: OCCASIONAL
  description: >
    Regression of previously acquired skills occurs in approximately 14% of
    individuals, often involving language and psychosocial domains. Potential
    triggers include illness and seizures.
  phenotype_term:
    preferred_term: Developmental regression
    term:
      id: HP:0002376
      label: Developmental regression
  evidence:
  - reference: DOI:10.1136/jmg-2023-109702
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Developmental regression occurred in 11/80 (14%) individuals across motor, language and psychosocial domains"
    explanation: >
      Regression is a recognized but minority feature, across multiple
      developmental domains.
- category: Behavioral
  name: Autistic behavior
  frequency: FREQUENT
  description: >
    Autism spectrum features are common, including impaired social interaction,
    repetitive behaviors, and restricted interests.
  phenotype_term:
    preferred_term: Autistic behavior
    term:
      id: HP:0000729
      label: Autistic behavior
  evidence:
  - reference: PMID:39746677
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Behavioral disorders, such as autism spectrum disorder (38%), were common."
    explanation: >
      Large clinical cohort (n=65) at Boston Children's Hospital Kleefstra Clinic
      found ASD in 38% of individuals, directly supporting autistic behavior as
      a frequent phenotype.
- category: Behavioral
  name: Sleep disturbances
  frequency: FREQUENT
  description: >
    Sleep problems are very common, reported in 63% of a large cohort (65/103).
    May include difficulty falling asleep, frequent nocturnal awakenings,
    and excessive daytime somnolence.
  phenotype_term:
    preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  notes: >
    Sleep disturbance frequency (63%) based on Morison et al. 2024 cohort
    of 103 individuals.
  evidence: []
- category: Craniofacial
  name: Distinctive facial features
  description: >
    Characteristic craniofacial features include brachycephaly, midface
    hypoplasia (flat midface), hypertelorism, synophrys, anteverted nares,
    cupid bow or tented upper lip, everted lower lip, prognathism, and
    macroglossia. The facial gestalt becomes more recognizable with age.
  phenotype_term:
    preferred_term: Flat face
    term:
      id: HP:0012368
      label: Flat face
  evidence:
  - reference: PMID:16826528
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "brachycephaly, flat face with hypertelorism, synophrys, anteverted nares, cupid bow or tented upper lip, everted lower lip, prognathism, macroglossia"
    explanation: >
      The original characterization provides the full description of the
      distinctive facial phenotype.
- category: Craniofacial
  name: Brachycephaly
  description: >
    Short anteroposterior head diameter (brachycephaly) is characteristic.
  phenotype_term:
    preferred_term: Brachycephaly
    term:
      id: HP:0000248
      label: Brachycephaly
  evidence:
  - reference: PMID:16826528
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "brachycephaly, flat face with hypertelorism"
    explanation: >
      Brachycephaly is listed as a core craniofacial feature in the original
      syndrome description.
- category: Craniofacial
  name: Hypertelorism
  description: >
    Widely spaced eyes are a common facial feature.
  phenotype_term:
    preferred_term: Hypertelorism
    term:
      id: HP:0000316
      label: Hypertelorism
  evidence:
  - reference: PMID:16826528
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "flat face with hypertelorism, synophrys, anteverted nares"
    explanation: >
      Hypertelorism is listed among the core craniofacial features.
- category: Cardiovascular
  name: Congenital heart defects
  frequency: FREQUENT
  description: >
    Structural cardiac defects occur in approximately 40% of patients (26/65
    in a large clinical cohort). Types include ventricular septal defects,
    atrial septal defects, and tetralogy of Fallot.
  phenotype_term:
    preferred_term: Congenital heart defect
    term:
      id: HP:0001627
      label: Abnormal heart morphology
  evidence:
  - reference: PMID:39746677
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Systemic health issues included structural cardiac defects (40%), hearing loss (32%), and constipation (31%)."
    explanation: >
      Large clinical cohort (n=65) found structural cardiac defects in 40%
      of individuals with Kleefstra syndrome.
- category: Metabolic
  name: Obesity
  frequency: FREQUENT
  description: >
    Childhood-onset obesity occurs frequently, potentially related to
    hypothalamic dysregulation or behavioral factors.
  phenotype_term:
    preferred_term: Obesity
    term:
      id: HP:0001513
      label: Obesity
  notes: >
    Childhood-onset obesity is a recognized feature but no specific
    prevalence data with quotable abstract snippet is available.
  evidence: []
genetic:
- name: EHMT1 haploinsufficiency (9q34.3 deletion)
  association: Causative
  gene_term:
    preferred_term: EHMT1
    term:
      id: hgnc:24650
      label: EHMT1
  features: >
    Approximately half of Kleefstra syndrome cases result from submicroscopic
    deletions at 9q34.3 encompassing EHMT1. The minimal critical region is
    less than 1 Mb comprising the EHMT1 gene. Deletion size varies, and larger
    deletions may include additional genes contributing to phenotypic variability.
    Almost all cases are de novo.
  inheritance:
  - name: Autosomal dominant inheritance
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
  evidence:
  - reference: PMID:16826528
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The minimal critical region responsible for this 9q subtelomeric deletion (9q-) syndrome has been estimated to be <1 Mb and comprises the euchromatin histone methyl transferase 1 gene (EHMT1)"
    explanation: >
      Establishes that the minimal critical deletion region includes EHMT1
      and is less than 1 Mb.
  - reference: PMID:16826528
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we identified two de novo mutations--a nonsense mutation and a frameshift mutation--in the EHMT1 gene in patients with a typical 9q- phenotype"
    explanation: >
      Demonstrates that intragenic EHMT1 mutations cause the same phenotype
      as deletions, proving EHMT1 haploinsufficiency is causative.
  - reference: CGGV:assertion_db91a861-6a88-4848-b6d5-4772bdef52ff-2018-06-06T100000.000Z
    reference_title: "EHMT1 / Kleefstra syndrome (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "EHMT1 | HGNC:24650 | Kleefstra syndrome | MONDO:0012455 | AD | Definitive"
    explanation: ClinGen classifies the EHMT1-Kleefstra syndrome gene-disease relationship as definitive with autosomal dominant inheritance.
- name: EHMT1 intragenic pathogenic variants
  association: Causative
  gene_term:
    preferred_term: EHMT1
    term:
      id: hgnc:24650
      label: EHMT1
  features: >
    Approximately half of cases are due to intragenic loss-of-function mutations
    in EHMT1, including nonsense, frameshift, splice-site, and missense variants
    affecting the catalytic SET domain or ankyrin repeat reader domain. A 2024
    study of 209 individuals used DNA methylation episignatures to reclassify
    191 variants as likely pathogenic/pathogenic, with domain-specific effects
    associating with differing phenotype severity.
  inheritance:
  - name: Autosomal dominant inheritance
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
  evidence:
  - reference: PMID:16826528
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These results establish that haploinsufficiency of EHMT1 is causative for 9q subtelomeric deletion syndrome"
    explanation: >
      Original paper proving EHMT1 intragenic mutations cause the syndrome.
- name: KMT2C loss-of-function variants
  association: Causative
  gene_term:
    preferred_term: KMT2C
    term:
      id: hgnc:13726
      label: KMT2C
  features: >
    Heterozygous loss-of-function mutations in KMT2C (MLL3), encoding a histone
    H3 lysine 4 methyltransferase, cause Kleefstra syndrome 2 (MONDO:0054701).
    Phenotypically overlaps with Kleefstra syndrome 1 but involves a distinct
    chromatin-modifying gene on a different chromosome.
  inheritance:
  - name: Autosomal dominant inheritance
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
  evidence: []
  notes: >
    KMT2C is identified as the causative gene for Kleefstra syndrome 2
    in OMIM and Mondo. Evidence items with specific PMID citations for
    KMT2C variants in KS2 can be added when available.
treatments:
- name: Speech and Language Therapy
  description: >
    Speech therapy is utilized by 97% of individuals in the largest cohort
    (100/103). Communication aids such as sign language and speech-generating
    devices are crucial for 59% of individuals.
  treatment_term:
    preferred_term: speech therapy
    term:
      id: MAXO:0000930
      label: speech therapy
  evidence:
  - reference: DOI:10.1136/jmg-2023-109702
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Communication aids, such as sign and speech-generating devices, were crucial for 61/103 (59%) individuals including those who were minimally verbal, had a speech disorder or following regression"
    explanation: >
      High utilization of speech therapy and communication aids demonstrates
      centrality of speech/language intervention in KS management.
- name: Early Intervention and Rehabilitation
  description: >
    Early developmental intervention is the cornerstone of management.
    Occupational therapy (86%), physiotherapy (89%), and speech therapy (97%)
    are utilized by the vast majority of individuals.
  treatment_term:
    preferred_term: early intervention services
    term:
      id: MAXO:0009101
      label: early intervention services
  evidence:
  - reference: DOI:10.1136/jmg-2023-109702
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early access to communication aids may improve communication and quality of life"
    explanation: >
      Evidence supports early intervention for improved communication
      outcomes in KS.
- name: Antiepileptic Drug Therapy
  description: >
    Standard antiepileptic medications are used to manage seizures in the
    approximately 12% of patients who develop epilepsy. Seizure type
    guides drug selection.
  treatment_term:
    preferred_term: antiepileptic drug therapy
    term:
      id: MAXO:0000167
      label: anticonvulsant agent therapy
- name: Behavioral Management
  description: >
    Behavioral interventions for autism spectrum features, sleep disturbances,
    and challenging behaviors. May include applied behavior analysis and
    structured behavioral support.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
datasets: []

📚

References & Deep Research

Deep Research

1

Falcon ▸

Disease Pathophysiology Research Template

Edison Scientific Literature 40 citations 2026-03-20T00:05:25.052529

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

Disease Name: Kleefstra Syndrome
MONDO ID: (if available)
Category: Mendelian

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Kleefstra Syndrome. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

What are the primary pathophysiological mechanisms?
What molecular pathways are dysregulated?
What cellular processes are affected?

2. Key Molecular Players

Genes/Proteins: Which genes are causally involved or implicated?
Chemical Entities: What metabolites, drugs, or small molecules are relevant?
Cell Types: Which cell types are primarily affected?
Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

What biological processes (GO terms) are disrupted?
Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

Where in the cell do key processes occur?
Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

What is the sequence of events from initial trigger to clinical manifestation?
Are there distinct stages or phases?

6. Phenotypic Manifestations

What are the key clinical phenotypes?
How do they relate to the underlying mechanisms?

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic claims
Prioritize recent reviews and landmark papers
Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Comprehensive Research Report: Kleefstra Syndrome Pathophysiology (EHMT1 haploinsufficiency)

0. Disease identifiers and scope

Disease: Kleefstra syndrome (classically “Kleefstra syndrome 1”, due to 9q34.3 microdeletion including EHMT1 or intragenic pathogenic EHMT1 variants). (frega2019neuronalnetworkdysfunction pages 1-2, morison2024expandingthephenotype pages 5-7)
MONDO ID: MONDO:0012455 (Open Targets disease entity “Kleefstra syndrome”). (balogh2024establishmentofhuman media 76d9168d)
Genetic category: Mendelian (autosomal dominant; typically de novo). (frega2019neuronalnetworkdysfunction pages 1-2, morison2024expandingthephenotype pages 5-7)

This report focuses on molecular/cellular mechanisms linked to EHMT1 haploinsufficiency and its downstream neurodevelopmental consequences, emphasizing 2023–2024 literature while incorporating key mechanistic primary studies that define core pathways.

1) Key concepts and definitions (current understanding)

1.1 Core genetic and epigenetic mechanism

EHMT1 (euchromatic histone lysine methyltransferase 1) encodes a chromatin-modifying enzyme that functions with EHMT2 (G9a) to methylate histone H3 lysine 9, producing repressive marks H3K9me1/H3K9me2 associated with transcriptional silencing and chromatin compaction. (frega2019neuronalnetworkdysfunction pages 1-2, hnizda2025denovoheterozygous pages 1-6)
Kleefstra syndrome results from heterozygous loss-of-function of EHMT1 (haploinsufficiency), causing reduced EHMT1 dosage and broad transcriptional dysregulation during neurodevelopment. (frega2019neuronalnetworkdysfunction pages 1-2, rots2024comprehensiveehmt1variants pages 1-3)

1.2 Pathophysiology as a “chromatinopathy” → circuit disorder

A recurring conceptual model is: epigenetic dysregulation → altered neuronal differentiation/maturation programs → synaptic dysfunction → network-level dysfunction → neurodevelopmental phenotypes (ID/ASD, speech/language impairment, hypotonia, epilepsy, etc.). Direct evidence for the circuit step is strong in human iPSC-derived neuronal network models and in Ehmt1+/− mice. (frega2019neuronalnetworkdysfunction pages 1-2, balogh2024establishmentofhumana pages 1-2)

1.3 Molecular biomarker concept: DNA methylation episignature

Because EHMT1 affects chromatin and gene regulation, peripheral blood DNA methylation (DNAm) “episignatures” can serve as molecular fingerprints aiding diagnosis and variant interpretation. A large 2024 AJHG cohort used DNAm signatures to reclassify variants and refine genotype–phenotype relationships. (rots2024comprehensiveehmt1variants pages 1-3)

2) Core pathophysiology: primary mechanisms, dysregulated pathways, cellular processes

2.1 Loss of H3K9me2 repression and specific promoter de-repression (GRIN1)

A key mechanistic link is the EHMT1 → H3K9me2 → GRIN1/NMDAR1 axis. In a human iPSC-derived excitatory cortical neuron model, Kleefstra syndrome neuronal networks showed a distinctive bursting phenotype, and the authors report:

Direct quote (abstract): “We show that these changes are mediated by upregulation of NMDA receptor (NMDAR) subunit 1 correlating with reduced deposition of the repressive H3K9me2 mark, the catalytic product of EHMT1, at the GRIN1 promoter.” (Frega et al., Nat Commun 2019; DOI: https://doi.org/10.1038/s41467-019-12947-3; PMID: 31695196) (frega2019neuronalnetworkdysfunction pages 1-2)

Thus, EHMT1 deficiency can de-repress specific neuronal genes via reduced local H3K9me2, providing a concrete example of how chromatin dysregulation becomes a synaptic/circuit phenotype.

2.2 Neuronal network dysfunction and excitatory/inhibitory balance

Network-level phenotypes in KS human iPSC-derived neuronal networks include reduced burst rate, longer burst duration, and increased temporal irregularity, with causal evidence from CRISPR-engineered EHMT1 disruption and pharmacological rescue by NMDAR antagonism. (frega2019neuronalnetworkdysfunction pages 1-2, frega2019neuronalnetworkdysfunction pages 5-6)
In addition to NMDAR-driven effects, homeostatic plasticity adaptations are implicated: in KS networks, transient NMDAR blockade triggered homeostatic changes consistent with synaptic upscaling involving GluA2-lacking AMPAR insertion (inferred from Naspm sensitivity during recovery). (frega2019neuronalnetworkdysfunction pages 5-6)

2.3 REST/NRSF–miRNA axis: dysregulated neuronal gene repression and developmental timing

A second major mechanism links EHMT1 to the neuron-specific transcriptional repressor REST (NRSF) through microRNA-mediated regulation. Alsaqati et al. show that EHMT1 inhibition or haploinsufficiency leads to derepression of multiple miRNAs that target REST, reducing REST protein and de-repressing neuronal gene programs prematurely.

Quantitative regulatory features include: 56 miRNAs upregulated >2.5-fold after EHMT1 inhibition; 11 of these were predicted REST-targeting miRNAs (including miR-142, miR-153-1, miR-26a-2). (Alsaqati et al., Transl Psychiatry 2022; DOI: https://doi.org/10.1038/s41398-022-02199-z; PMID: 36241675) (alsaqati2022nrsfrestliesat pages 3-5)
Mechanistic detail: ChIP-qPCR did not show H3K9me2 at the REST promoter, but did detect H3K9me2 at miRNA TSSs (e.g., miR-142/153/26a), consistent with EHMT1 controlling REST indirectly via miRNA repression. (alsaqati2022nrsfrestliesat pages 3-5)
Functional rescue: expressing a miRNA-insensitive REST transcript (REST-ΔUTR) prevented aberrant REST-target activation, supporting causality. (alsaqati2022nrsfrestliesat pages 3-5)

This axis provides a molecular explanation for altered neurodevelopmental timing (premature neuronal gene expression and differentiation trajectories) and a bridge between epigenetic and post-transcriptional regulation. (alsaqati2022nrsfrestliesat pages 1-2, alsaqati2022nrsfrestliesat pages 3-5)

2.4 Synaptogenesis/connectivity deficits despite neurite overgrowth

In a 2024 iPSC-derived 3D cortical neurosphere (“corticoid”) model of KS, neurite outgrowth was increased, yet synaptic protein markers indicated reduced synaptic maturation/connectivity: - PSD95 and synaptophysin (SYP) expression in neurites were lower in KS; PSD95 reduction reached significance (p = 0.01). (Balogh et al., Sci Rep 2024; DOI: https://doi.org/10.1038/s41598-024-72791-4) (balogh2024establishmentofhumana pages 5-7)

This supports a concept of mis-timed or mis-specified neurodevelopment: neuronal projections may form exuberantly while synapse assembly/stabilization is impaired.

2.5 Metabolic/oxidative stress vulnerability as a modifier mechanism

Balogh et al. extended KS pathophysiology into metabolic/toxicant sensitivity, with two notable results: 1) KS neural cultures showed differential toxicant sensitivity depending on developmental stage (NPC vs mature 3D spheroids), and KS 3D spheroids were particularly sensitive to paraquat. (balogh2024establishmentofhumana pages 5-7, balogh2024establishmentofhuman media d449cbce)
2) LDHA transcript was significantly downregulated in KS NPCs (p = 0.03) and KS 3D spheroids (p = 0.002), suggesting altered metabolic adaptation to oxidative stress conditions. (balogh2024establishmentofhumana pages 7-8)

These findings motivate investigation of energy metabolism and oxidative stress response as potential contributors to variable neurodevelopmental outcomes and environmental sensitivity.

3) Key molecular players (genes/proteins, chemicals, cells, anatomy)

3.1 Genes/proteins (causal and mechanistic)

EHMT1 (HGNC: EHMT1): causal gene; H3K9 methyltransferase; key epigenetic regulator. (frega2019neuronalnetworkdysfunction pages 1-2, rots2024comprehensiveehmt1variants pages 1-3)
EHMT2 (G9a): functional partner; shared enzymatic complex with EHMT1. (frega2019neuronalnetworkdysfunction pages 1-2, hnizda2025denovoheterozygous pages 1-6)
GRIN1 / NMDAR1: de-repressed in EHMT1 deficiency; drives network dysfunction and pharmacologically rescuable hyperfunction. (frega2019neuronalnetworkdysfunction pages 1-2)
REST/NRSF: reduced at protein level via miRNA derepression in EHMT1 deficiency; de-represses neuronal target genes and shifts neurodevelopmental timing. (alsaqati2022nrsfrestliesat pages 3-5, alsaqati2022nrsfrestliesat pages 1-2)
BDNF: increased expression associated with altered neurite outgrowth in KS spheroids and referenced as REST-linked. (balogh2024establishmentofhumana pages 7-8)
Synaptic markers: DLG4 (PSD95), SYP. (balogh2024establishmentofhumana pages 5-7)
Metabolic genes: LDHA, LDHB (LDHA downregulated in KS). (balogh2024establishmentofhumana pages 7-8)

Additionally, Open Targets lists KMT2C as strongly associated with the Kleefstra syndrome spectrum (reflecting “Kleefstra syndrome 2” concept in literature), although canonical KS is EHMT1-driven. (balogh2024establishmentofhuman media 76d9168d)

3.2 Chemical entities and small molecules relevant to mechanisms

NMDAR antagonists used experimentally for rescue: D-AP5/APV (experimental reagent); NMDA pathway involvement. (frega2019neuronalnetworkdysfunction pages 5-6, frega2019neuronalnetworkdysfunction pages 1-2)
Toxicants for differential sensitivity assays: paraquat, rotenone, bardoxolone methyl (CDDO-Me), doxorubicin. (balogh2024establishmentofhumana pages 5-7, balogh2024establishmentofhuman media d449cbce)

3.3 Cell types (primary affected/implicated)

Mechanistic studies implicate human excitatory cortical neurons and developing neural progenitors, with evidence for neuronal subtype shifts in 3D systems: - excitatory cortical neurons derived from iPSCs (network phenotypes). (frega2019neuronalnetworkdysfunction pages 1-2) - cortical spheroids enriched for VGLUT1/2+ glutamatergic and ChAT+ cholinergic neurons, with underrepresentation of TH+ catecholaminergic neurons. (balogh2024establishmentofhumana pages 1-2, balogh2024establishmentofhumana pages 7-8)

3.4 Anatomical systems and tissues

Central nervous system emphasis: cerebral cortex (most direct model evidence) and broader brain networks. (frega2019neuronalnetworkdysfunction pages 1-2, balogh2024establishmentofhumana pages 1-2)
Multi-system involvement in patients includes cardiac conditions and sensory impairments, consistent with pleiotropic roles of EHMT1. (morison2024expandingthephenotype pages 5-7)

4) Biological processes and cellular components (GO-oriented)

Ontology-oriented candidate annotations are summarized in the embedded table below.

Mechanism	Key gene/protein (HGNC)	Suggested pathway/process (GO BP)	Cellular component (GO CC)	Principal cell type(s) (CL)	Anatomy (UBERON)	Key chemicals/small molecules (CHEBI)	Supporting evidence + PMID
EHMT1 haploinsufficiency reduces EHMT1/EHMT2-mediated H3K9me2 repression, altering transcriptional control	EHMT1, EHMT2, Histone H3, GRIN1	histone H3-K9 dimethylation; negative regulation of transcription by RNA polymerase II; chromatin organization	nucleus; chromatin; nucleoplasm	excitatory cortical neuron (CL:0000540)	cerebral cortex (UBERON:0000956); brain (UBERON:0000955)	S-adenosyl-L-methionine / SAM (CHEBI:15414)	KS iNeurons show reduced H3K9me2; EHMT1 is causal for KLEFS and functions with EHMT2 as H3K9 methyltransferase (frega2019neuronalnetworkdysfunction pages 1-2, hnizda2025denovoheterozygous pages 1-6, rots2024comprehensiveehmt1variants pages 1-3) PMID: 31695196
GRIN1/NMDAR1 upregulation drives abnormal network bursting; NMDAR antagonism rescues network phenotype	GRIN1, EHMT1	regulation of postsynaptic membrane potential; synaptic signaling; neuronal network activity; homeostatic synaptic plasticity	postsynaptic density; glutamatergic synapse; neuronal cell body	excitatory neuron (CL:0000540)	cerebral cortex (UBERON:0000956)	NMDA (CHEBI:16261); D-AP5/APV (CHEBI not established here); Naspm (CHEBI not established here)	“reduced deposition of the repressive H3K9me2 mark… at the GRIN1 promoter” with reduced burst rate, longer duration, irregularity; D-AP5 suppressed KS network bursting and rescued phenotype (frega2019neuronalnetworkdysfunction pages 1-2, frega2019neuronalnetworkdysfunction pages 5-6, balogh2024establishmentofhumana pages 1-2) PMID: 31695196
EHMT1 loss decreases REST/NRSF via miRNA derepression, causing abnormal neuronal gene expression and altered neurodevelopmental timing	EHMT1, REST (NRSF), miRNAs	negative regulation of neuron differentiation; regulation of miRNA-mediated gene silencing; regulation of transcription by RNA polymerase II	nucleus; chromatin; miRISC-associated cytoplasmic compartments	induced pluripotent stem cell-derived neuron; neural progenitor cell	forebrain (UBERON:0001890); brain (UBERON:0000955)	microRNA (CHEBI:33697)	Reduced EHMT1 activity decreases REST/NRSF protein indirectly through miRNA repression defects, altering neuronal gene expression/progression of neurodevelopment (wood2024theepigeneticnetwork pages 1-5, tzetis2025anovelframeshift pages 4-6, ren2024clinicalcharacteristicsand pages 12-12) PMID: 36241675
BDNF promoter hypomethylation/increased expression is linked to excessive neurite outgrowth	BDNF, EHMT1, REST	axonogenesis; neuron projection development; regulation of neurotrophin signaling pathway	neuronal projection; growth cone; nucleus	cortical neuron (CL:0000540)	cerebral cortex (UBERON:0000956); hippocampus (UBERON:0002421)	brain-derived neurotrophic factor / BDNF (protein; no CHEBI); acetylcholine (CHEBI:15355)	KS spheroids had longer/more branched neurites and higher BDNF; cited evidence links Ehmt1 loss to BDNF promoter hypomethylation and REST-target derepression (balogh2024establishmentofhumana pages 7-8, balogh2024establishmentofhumana pages 1-2) PMID: not provided in retrieved texts
Synaptogenesis/connectivity deficit with reduced PSD95 and SYP despite increased neurite outgrowth	DLG4 (PSD95), SYP, EHMT1	synapse organization; chemical synaptic transmission; postsynapse assembly	postsynaptic density; synaptic vesicle membrane; excitatory synapse	cortical neuron (CL:0000540)	cerebral cortex (UBERON:0000956)	none specifically established	In KS neurites, PSD95 and SYP were lower, with PSD95 significant (p=0.01), indicating impaired synaptogenesis/connectivity despite neurite overgrowth (balogh2024establishmentofhumana pages 5-7, balogh2024establishmentofhumana pages 7-8) PMID: not provided in retrieved texts
Altered neuronal subtype balance: excess glutamatergic/cholinergic markers and reduced catecholaminergic neurons	SLC17A7/SLC17A6 (VGLUT1/2), CHAT, TH, GRIN1	neuron differentiation; neurotransmitter transport; regulation of excitatory postsynaptic potential	synapse; synaptic vesicle; postsynaptic membrane	glutamatergic neuron (CL:0000679); cholinergic neuron (CL:0000108); catecholaminergic neuron (CL:0000700)	cerebral cortex (UBERON:0000956)	glutamate (CHEBI:29985); acetylcholine (CHEBI:15355); dopamine/catecholamine-related small molecules (CHEBI:18243 for dopamine)	KS spheroids were enriched for VGLUT1/2+ and ChAT+ neurons, with TH+ neurons underrepresented; NMDAR1 high as a KS marker (balogh2024establishmentofhumana pages 1-2, balogh2024establishmentofhumana pages 7-8) PMID: not provided in retrieved texts
Oxidative-stress vulnerability and metabolic adaptation defects with LDHA downregulation	LDHA, LDHB, EHMT1	response to oxidative stress; pyruvate metabolic process; lactate metabolic process	cytosol; mitochondrion	neural progenitor cell (CL:0000031); cortical spheroid neuron	cerebral cortex (UBERON:0000956); developing brain (UBERON:0001016)	paraquat (CHEBI:34905); rotenone (CHEBI:28262); bardoxolone methyl/CDDO-Me (CHEBI not established here); doxorubicin (CHEBI:28748); lactate (CHEBI:24996); pyruvate (CHEBI:15361)	KS spheroids showed greater toxicant sensitivity, especially paraquat (EC50 4.8 vs 23.7 µM control) and rotenone (0.11 vs 0.23 µM), and LDHA was downregulated in NPCs (p=0.03) and 3D spheroids (p=0.002) (balogh2024establishmentofhumana pages 5-7, balogh2024establishmentofhumana pages 7-8, balogh2024establishmentofhuman media d449cbce) PMID: not provided in retrieved texts
DNA methylation episignature as a molecular biomarker; variant/domain effects refine mechanism and diagnosis	EHMT1, EHMT2	DNA methylation; epigenetic regulation of gene expression; chromatin organization	chromatin; nucleus; peripheral blood leukocyte nucleus	leukocyte (CL:0000738)	blood (UBERON:0000178)	5-methylcytosine (CHEBI:49108)	2024 AJHG study of 209 individuals used DNAm signatures to classify EHMT1 variants; ankyrin-reader disruption could yield KLEFS1 episignature, whereas SET-only loss did not consistently produce canonical DNAm signature/phenotype (rots2024comprehensiveehmt1variants pages 1-3, barrero2024ehmt2lossoffunctionalterations pages 4-7) PMID: not provided in retrieved texts

Table: This table summarizes core molecular and cellular mechanisms implicated in Kleefstra syndrome, linking each mechanism to genes, ontology-ready biological processes and compartments, affected cell types and anatomy, relevant chemicals, and evidence sources. It is useful as a compact knowledge-base scaffold for annotation and evidence tracking.

Key GO biological-process themes supported by evidence include: - Histone H3K9 methylation and negative regulation of transcription (EHMT1/EHMT2). (frega2019neuronalnetworkdysfunction pages 1-2) - Regulation of synaptic signaling and homeostatic synaptic plasticity, including NMDAR-dependent network activity. (frega2019neuronalnetworkdysfunction pages 1-2, frega2019neuronalnetworkdysfunction pages 5-6) - miRNA-mediated post-transcriptional regulation affecting neuronal differentiation timing (REST axis). (alsaqati2022nrsfrestliesat pages 3-5)

Cellular component themes include nucleus/chromatin (epigenetic regulation) and synaptic compartments such as postsynaptic density (PSD95) and glutamatergic synapses (NMDAR1). (balogh2024establishmentofhumana pages 5-7, frega2019neuronalnetworkdysfunction pages 1-2)

5) Disease progression model (sequence of events)

A synthesis consistent with current data: 1) Initial trigger: heterozygous loss-of-function in EHMT1 (or deletion of 9q34.3 including EHMT1) → reduced EHMT1 dosage. (frega2019neuronalnetworkdysfunction pages 1-2, morison2024expandingthephenotype pages 5-7)
2) Primary molecular event: reduced EHMT1/EHMT2 complex activity and/or altered reader/writer functions → reduced local or global repressive chromatin marks (e.g., H3K9me2) and altered transcriptional regulation; plus indirect effects via miRNA networks. (frega2019neuronalnetworkdysfunction pages 1-2, alsaqati2022nrsfrestliesat pages 3-5, rots2024comprehensiveehmt1variants pages 1-3)
3) Developmental program disruption: premature or aberrant expression of neuronal genes due to REST reduction and altered miRNA dynamics; altered neuronal subtype specification and/or maturation timing. (alsaqati2022nrsfrestliesat pages 3-5, balogh2024establishmentofhumana pages 7-8)
4) Synaptic/circuit dysfunction: reduced synaptic marker expression (PSD95/SYP), abnormal glutamatergic signaling with NMDAR1 upregulation, abnormal bursting patterns and compensatory homeostatic plasticity. (balogh2024establishmentofhumana pages 5-7, frega2019neuronalnetworkdysfunction pages 1-2, frega2019neuronalnetworkdysfunction pages 5-6)
5) Clinical manifestation: neurodevelopmental disorder phenotype—ID, severe speech disorder, autistic traits, hypotonia, epilepsy and multi-system features. (morison2024expandingthephenotype pages 5-7, morison2024expandingthephenotype pages 1-3)

A key unresolved issue is developmental critical windows (prenatal vs postnatal) for reversibility, which remains an area of active research and is emphasized as a major translational question for histone methyltransferase-related NDDs. (roth2023histonelysinemethyltransferaserelated pages 7-9)

6) Phenotypic manifestations and mechanistic links (with 2024 statistics)

A large 2024 cohort (n=103) provides updated, actionable phenotype frequencies and functional-impact measures: - Epilepsy: 12/103 (12%). (Morison et al., J Med Genet 2024; DOI: https://doi.org/10.1136/jmg-2023-109702) (morison2024expandingthephenotype pages 5-7) - Sleep disturbance: 65/103 (63%). (morison2024expandingthephenotype pages 5-7) - Cardiac conditions: 33/103 (32%). (morison2024expandingthephenotype pages 5-7) - MRI abnormalities: 38/79 (48%). (morison2024expandingthephenotype pages 5-7) - Cognitive distribution (n=79 assessed): 67/79 (85%) had ID (mild 20%, moderate 48%, severe 15%); 12/79 (15%) had average cognitive ability. (morison2024expandingthephenotype pages 5-7, morison2024expandingthephenotype pages 7-8) - Language distribution (n=90 assessed): average 10/90 (11%); severe impairment 53/90 (59%). (morison2024expandingthephenotype pages 1-3) - Speech disorder among verbal individuals: 48/49 (98%) had a speech disorder; dysarthria 34/49 (69%); childhood apraxia of speech 29/49 (59%). (morison2024expandingthephenotype pages 8-10) - Regression: 11/80 (14%), often involving language and psychosocial domains; potential triggers included illness and seizures. (morison2024expandingthephenotype pages 7-8) - AAC use: 61/103 (59%), emphasizing real-world implementation of communication supports. (morison2024expandingthephenotype pages 1-3)

Mechanistic alignment: high burden of speech disorder and neurodevelopmental variability is consistent with EHMT1-dependent disruption of neuronal gene programs and network function (REST/miRNA and NMDAR axes). (alsaqati2022nrsfrestliesat pages 3-5, frega2019neuronalnetworkdysfunction pages 1-2)

7) Recent developments (2023–2024) and latest research themes

7.1 2024: Variant interpretation, genotype–mechanism insights, and episignatures

A major 2024 AJHG study recruited 209 individuals with rare EHMT1 variants and reclassified 191 as likely pathogenic/pathogenic using combined in silico/in vitro evidence and DNAm signature analysis. (Rots et al., AJHG 2024; DOI: https://doi.org/10.1016/j.ajhg.2024.06.008) (rots2024comprehensiveehmt1variants pages 1-3) Key mechanistic interpretation from this cohort: disruption of EHMT1 functional domains (e.g., ankyrin repeat “reader” vs SET “writer” effects) can associate with differing DNAm signature presence and phenotype severity, supporting a more nuanced model than “global loss of methyltransferase activity alone.” (rots2024comprehensiveehmt1variants pages 1-3)

7.2 2024: Human 3D cortical neurosphere models for pathomechanisms and screening

Balogh et al. established a patient-derived cortical spheroid model that recapitulates disease-associated traits and is positioned for drug/toxicant screening. (Balogh et al., Sci Rep 2024; DOI: https://doi.org/10.1038/s41598-024-72791-4) (balogh2024establishmentofhumana pages 1-2) Quantitative toxicant data include EC50 shifts in KS vs control, especially in 3D spheroids (Table 1/Figure 4). For example: - Paraquat EC50 (3D spheroids): control 23.7 µM vs KS 4.8 µM. (balogh2024establishmentofhuman media d449cbce) - Rotenone EC50 (3D spheroids): control 0.23 µM vs KS 0.11 µM. (balogh2024establishmentofhuman media d449cbce)

7.3 2023: Therapeutic concept reviews for histone methyltransferase haploinsufficiency disorders

A 2023 Frontiers review highlights emerging interest in gene-upregulation strategies (e.g., RNA activation / saRNA) as a conceptual match for haploinsufficiency disorders (contrasting with oncology, where inhibitors dominate). The review emphasizes key barriers—particularly delivery to brain—and recommends patient-derived neuronal 2D/3D models for preclinical testing. (Roth et al., Front Cell Dev Biol 2023; DOI: https://doi.org/10.3389/fcell.2023.1090046) (roth2023histonelysinemethyltransferaserelated pages 7-9, roth2023histonelysinemethyltransferaserelated pages 6-7)

8) Current applications and real-world implementations

8.1 Clinical phenotyping and care

The 2024 cohort shows very high utilization of supportive therapies: - occupational therapy 87/101 (86%), physiotherapy 90/101 (89%), speech therapy 100/103 (97%). (morison2024expandingthephenotype pages 7-8) AAC use in 59% of individuals reflects real-world implementation of assistive communication as a core management component. (morison2024expandingthephenotype pages 1-3)

8.2 Molecular diagnostics: episignatures / EpiSign-style approaches

The 2024 AJHG variant study explicitly integrates DNAm signatures to support diagnosis and variant classification, representing a practical implementation of clinical epigenomics in KS. (rots2024comprehensiveehmt1variants pages 1-3)

8.3 Disease modeling for mechanism and screening

Human iPSC-derived excitatory cortical neuron networks and 3D cortical spheroids are now well-established platforms for: - mechanistic dissection (e.g., GRIN1 promoter repression and NMDAR hyperfunction), (frega2019neuronalnetworkdysfunction pages 1-2) - pharmacologic rescue assays (NMDAR antagonism), (frega2019neuronalnetworkdysfunction pages 1-2) - toxicant/drug sensitivity profiling with quantitative EC50 endpoints. (balogh2024establishmentofhuman media d449cbce)

9) Expert opinions and analysis (authoritative interpretations)

1) Mechanistic targeting of NMDAR signaling: Frega et al. conclude a “direct link” between EHMT1 deficiency and NMDAR hyperfunction and show pharmacological rescue of network phenotypes, supporting NMDAR pathway modulation as a rational, mechanism-based intervention concept (preclinical). (frega2019neuronalnetworkdysfunction pages 1-2)

2) Systems-level epigenetic-to-developmental timing effects: Alsaqati et al. frame EHMT1 as controlling REST/NRSF through miRNA repression, connecting chromatin regulation to neuronal gene program timing and to broader neuropsychiatric risk architecture (ID/schizophrenia enrichment in EHMT1-regulated miRNA sets). (alsaqati2022nrsfrestliesat pages 1-2, alsaqati2022nrsfrestliesat pages 3-5)

3) Therapeutic development constraints: Roth et al. emphasize that for HKMT-related NDDs, a major barrier is brain delivery and timing, arguing for rigorous testing in advanced human neuronal models (organoids/assembloids, BBB inclusion) to evaluate efficacy and safety of gene-activation approaches. (roth2023histonelysinemethyltransferaserelated pages 7-9)

10) Evidence items (PMIDs) and priority references (with URLs and dates)

High-priority mechanistic primary studies - Frega M. et al. Nature Communications (2019-10). “Neuronal network dysfunction in a model for Kleefstra syndrome mediated by enhanced NMDAR signaling.” DOI: https://doi.org/10.1038/s41467-019-12947-3. PMID: 31695196. (frega2019neuronalnetworkdysfunction pages 1-2) - Alsaqati M. et al. Translational Psychiatry (2022-10). “NRSF/REST lies at the intersection between epigenetic regulation, miRNA-mediated gene control and neurodevelopmental pathways…” DOI: https://doi.org/10.1038/s41398-022-02199-z. PMID: 36241675. (alsaqati2022nrsfrestliesat pages 1-2)

Recent (2023–2024) sources prioritized - Balogh A. et al. Scientific Reports (2024-09). “Establishment of human pluripotent stem cell-derived cortical neurosphere model…” DOI: https://doi.org/10.1038/s41598-024-72791-4. (PMID not available in retrieved text). (balogh2024establishmentofhumana pages 1-2) - Morison L.D. et al. Journal of Medical Genetics (2024-01). “Expanding the phenotype of Kleefstra syndrome: speech, language and cognition in 103 individuals.” DOI: https://doi.org/10.1136/jmg-2023-109702. (PMID not available in retrieved text). (morison2024expandingthephenotype pages 1-3) - Roth C. et al. Frontiers in Cell and Developmental Biology (2023-02). “Histone lysine methyltransferase-related neurodevelopmental disorders: current knowledge and saRNA future therapies.” DOI: https://doi.org/10.3389/fcell.2023.1090046. (PMID not available in retrieved text). (roth2023histonelysinemethyltransferaserelated pages 2-3) - Rots D. et al. American Journal of Human Genetics (2024-08). “Comprehensive EHMT1 variants analysis…” DOI: https://doi.org/10.1016/j.ajhg.2024.06.008. (PMID not available in retrieved text). (rots2024comprehensiveehmt1variants pages 1-3)

11) Limitations of this synthesis

Some 2024 papers in the retrieved corpus did not include PubMed identifiers in the extracted text; where PMIDs are absent above, they were not available from provided tool context and should be cross-checked in PubMed for knowledge-base ingestion. (balogh2024establishmentofhumana pages 1-2, rots2024comprehensiveehmt1variants pages 1-3, morison2024expandingthephenotype pages 1-3)

Figures/tables used

Balogh et al. 2024 Figure 4 and Table 1 (dose-response curves and EC50 values) were extracted as cropped images for quantitative support of toxicant sensitivity differences. (balogh2024establishmentofhuman media d449cbce, balogh2024establishmentofhuman media 76d9168d)

References

(frega2019neuronalnetworkdysfunction pages 1-2): Monica Frega, Katrin Linda, Jason M. Keller, Güvem Gümüş-Akay, Britt Mossink, Jon-Ruben van Rhijn, Moritz Negwer, Teun Klein Gunnewiek, Katharina Foreman, Nine Kompier, Chantal Schoenmaker, Willem van den Akker, Ilse van der Werf, Astrid Oudakker, Huiqing Zhou, Tjitske Kleefstra, Dirk Schubert, Hans van Bokhoven, and Nael Nadif Kasri. Neuronal network dysfunction in a model for kleefstra syndrome mediated by enhanced nmdar signaling. Nature Communications, Oct 2019. URL: https://doi.org/10.1038/s41467-019-12947-3, doi:10.1038/s41467-019-12947-3. This article has 164 citations and is from a highest quality peer-reviewed journal.
(morison2024expandingthephenotype pages 5-7): Lottie D. Morison, Milou G.P. Kennis, Dmitrijs Rots, Arianne Bouman, Joost Kummeling, Elizabeth Palmer, Adam P. Vogel, Frederique Liegeois, Amanda Brignell, Siddharth Srivastava, Zoe Frazier, Di Milnes, Himanshu Goel, David J. Amor, Ingrid E. Scheffer, Tjitske Kleefstra, and Angela T. Morgan. Expanding the phenotype of kleefstra syndrome: speech, language and cognition in 103 individuals. Journal of Medical Genetics, 61(6):578-585, Jan 2024. URL: https://doi.org/10.1136/jmg-2023-109702, doi:10.1136/jmg-2023-109702. This article has 21 citations and is from a domain leading peer-reviewed journal.
(balogh2024establishmentofhuman media 76d9168d): Andrea Balogh, Mária Bódi-Jakus, Vivien Réka Karl, Tamás Bellák, Balázs Széky, János Farkas, Federica Lamberto, David Novak, Anita Fehér, Melinda Zana, and András Dinnyés. Establishment of human pluripotent stem cell-derived cortical neurosphere model to study pathomechanisms and chemical toxicity in kleefstra syndrome. Scientific Reports, Sep 2024. URL: https://doi.org/10.1038/s41598-024-72791-4, doi:10.1038/s41598-024-72791-4. This article has 3 citations and is from a peer-reviewed journal.
(hnizda2025denovoheterozygous pages 1-6): Aleš Hnízda, Beatriz Martinez-Delgado, Diana Sanchez-Ponce, Javier Alonso, Jeanne Amiel, Tania Attie-Bitach, Ariadna Bada-Navarro, Beatriz Baladron, Eva Bermejo-Sanchez, Vítězslav Brinsa, Ivana Buková, Rosario Cazorla-Calleja, Sylvie Červenková, Shanshan Chow, Petr Dušek, Marta Fernandez, Sourav Ghosh, Gema Gomez-Mariano, Andrea Gřegořová, Mark James Hamilton, Hana Hartmannová, Esther Hernandez-San Miguel, Marina Herrero-Matesanz, Kateřina Hodaňová, Alan Kádek, Jennifer Kerkhof, Tjitske Kleefstra, Didier Lacombe, Michael A. Levy, Estrella Lopez-Martin, Ruaud Lyse, Petr Man, Purificacion Marin-Reina, Ellen F. Macnamara, Haley McConkey, Petra Melenovská, Lidia M. Mielu, David Moore, Lenka Mrázová, Karolína Musilová, Petr Nickl, Martina Pavlíková, Lea Pavlovičová, Manuel Posada, Jan Procházka, Kateryna Pysanenko, Sheila Ramos del Saz, Dmitrijs Rots, Jessica Rzasa, Radislav Sedláček, Viktor Stránecký, František Špoutil, Matthew L. Tedder, Louise Thompson, Cynthia J. Tifft, Frederic Tran Mau-Them, Helena Trešlová, Antonio Vitobello, Bekim Sadikovic, Jakub Sikora, Stanislav Kmoch, Maria J. Barrero, and Lenka Nosková. De novo heterozygous variants in ehmt2 genocopy kleefstra syndrome via loss of g9a methyltransferase activity. BioRxiv, Sep 2025. URL: https://doi.org/10.1101/2025.09.25.678439, doi:10.1101/2025.09.25.678439. This article has 0 citations.
(rots2024comprehensiveehmt1variants pages 1-3): Dmitrijs Rots, Arianne Bouman, Ayumi Yamada, Michael Levy, Alexander J.M. Dingemans, Bert B.A. de Vries, Martina Ruiterkamp-Versteeg, Nicole de Leeuw, Charlotte W. Ockeloen, Rolph Pfundt, Elke de Boer, Joost Kummeling, Bregje van Bon, Hans van Bokhoven, Nael Nadif Kasri, Hanka Venselaar, Marielle Alders, Jennifer Kerkhof, Haley McConkey, Alma Kuechler, Bart Elffers, Rixje van Beeck Calkoen, Susanna Hofman, Audrey Smith, Maria Irene Valenzuela, Siddharth Srivastava, Zoe Frazier, Isabelle Maystadt, Carmelo Piscopo, Giuseppe Merla, Meena Balasubramanian, Gijs W.E. Santen, Kay Metcalfe, Soo-Mi Park, Laurent Pasquier, Siddharth Banka, Dian Donnai, Daniel Weisberg, Gertrud Strobl-Wildemann, Annemieke Wagemans, Maaike Vreeburg, Diana Baralle, Nicola Foulds, Ingrid Scurr, Nicola Brunetti-Pierri, Johanna M. van Hagen, Emilia K. Bijlsma, Anna H. Hakonen, Carolina Courage, David Genevieve, Lucile Pinson, Francesca Forzano, Charu Deshpande, Maria L. Kluskens, Lindsey Welling, Astrid S. Plomp, Els K. Vanhoutte, Louisa Kalsner, Janna A. Hol, Audrey Putoux, Johanna Lazier, Pradeep Vasudevan, Elizabeth Ames, Jessica O'Shea, Damien Lederer, Julie Fleischer, Mary O'Connor, Melissa Pauly, Georgia Vasileiou, André Reis, Catherine Kiraly-Borri, Arjan Bouman, Chris Barnett, Marjan Nezarati, Lauren Borch, Gea Beunders, Kübra Özcan, Stéphanie Miot, Catharina M.L. Volker-Touw, Koen L.I. van Gassen, Gerarda Cappuccio, Katrien Janssens, Nofar Mor, Inna Shomer, Dan Dominissini, Matthew L. Tedder, Alison M. Muir, Bekim Sadikovic, Han G. Brunner, Lisenka E.L.M. Vissers, Yoichi Shinkai, and Tjitske Kleefstra. Comprehensive ehmt1 variants analysis broadens genotype-phenotype associations and molecular mechanisms in kleefstra syndrome. The American Journal of Human Genetics, 111:1605-1625, Aug 2024. URL: https://doi.org/10.1016/j.ajhg.2024.06.008, doi:10.1016/j.ajhg.2024.06.008. This article has 23 citations.
(balogh2024establishmentofhumana pages 1-2): Andrea Balogh, Mária Bódi-Jakus, Vivien Réka Karl, Tamás Bellák, Balázs Széky, János Farkas, Federica Lamberto, David Novak, Anita Fehér, Melinda Zana, and András Dinnyés. Establishment of human pluripotent stem cell-derived cortical neurosphere model to study pathomechanisms and chemical toxicity in kleefstra syndrome. Scientific Reports, Sep 2024. URL: https://doi.org/10.1038/s41598-024-72791-4, doi:10.1038/s41598-024-72791-4. This article has 3 citations and is from a peer-reviewed journal.
(frega2019neuronalnetworkdysfunction pages 5-6): Monica Frega, Katrin Linda, Jason M. Keller, Güvem Gümüş-Akay, Britt Mossink, Jon-Ruben van Rhijn, Moritz Negwer, Teun Klein Gunnewiek, Katharina Foreman, Nine Kompier, Chantal Schoenmaker, Willem van den Akker, Ilse van der Werf, Astrid Oudakker, Huiqing Zhou, Tjitske Kleefstra, Dirk Schubert, Hans van Bokhoven, and Nael Nadif Kasri. Neuronal network dysfunction in a model for kleefstra syndrome mediated by enhanced nmdar signaling. Nature Communications, Oct 2019. URL: https://doi.org/10.1038/s41467-019-12947-3, doi:10.1038/s41467-019-12947-3. This article has 164 citations and is from a highest quality peer-reviewed journal.
(alsaqati2022nrsfrestliesat pages 3-5): Mouhamed Alsaqati, Brittany A. Davis, Jamie Wood, Megan M. Jones, Lora Jones, Aishah Westwood, Olena Petter, Anthony R. Isles, David Linden, Marianne Van den Bree, Michael Owen, Jeremy Hall, and Adrian J. Harwood. Nrsf/rest lies at the intersection between epigenetic regulation, mirna-mediated gene control and neurodevelopmental pathways associated with intellectual disability (id) and schizophrenia. Translational Psychiatry, Oct 2022. URL: https://doi.org/10.1038/s41398-022-02199-z, doi:10.1038/s41398-022-02199-z. This article has 19 citations and is from a peer-reviewed journal.
(alsaqati2022nrsfrestliesat pages 1-2): Mouhamed Alsaqati, Brittany A. Davis, Jamie Wood, Megan M. Jones, Lora Jones, Aishah Westwood, Olena Petter, Anthony R. Isles, David Linden, Marianne Van den Bree, Michael Owen, Jeremy Hall, and Adrian J. Harwood. Nrsf/rest lies at the intersection between epigenetic regulation, mirna-mediated gene control and neurodevelopmental pathways associated with intellectual disability (id) and schizophrenia. Translational Psychiatry, Oct 2022. URL: https://doi.org/10.1038/s41398-022-02199-z, doi:10.1038/s41398-022-02199-z. This article has 19 citations and is from a peer-reviewed journal.
(balogh2024establishmentofhumana pages 5-7): Andrea Balogh, Mária Bódi-Jakus, Vivien Réka Karl, Tamás Bellák, Balázs Széky, János Farkas, Federica Lamberto, David Novak, Anita Fehér, Melinda Zana, and András Dinnyés. Establishment of human pluripotent stem cell-derived cortical neurosphere model to study pathomechanisms and chemical toxicity in kleefstra syndrome. Scientific Reports, Sep 2024. URL: https://doi.org/10.1038/s41598-024-72791-4, doi:10.1038/s41598-024-72791-4. This article has 3 citations and is from a peer-reviewed journal.
(balogh2024establishmentofhuman media d449cbce): Andrea Balogh, Mária Bódi-Jakus, Vivien Réka Karl, Tamás Bellák, Balázs Széky, János Farkas, Federica Lamberto, David Novak, Anita Fehér, Melinda Zana, and András Dinnyés. Establishment of human pluripotent stem cell-derived cortical neurosphere model to study pathomechanisms and chemical toxicity in kleefstra syndrome. Scientific Reports, Sep 2024. URL: https://doi.org/10.1038/s41598-024-72791-4, doi:10.1038/s41598-024-72791-4. This article has 3 citations and is from a peer-reviewed journal.
(balogh2024establishmentofhumana pages 7-8): Andrea Balogh, Mária Bódi-Jakus, Vivien Réka Karl, Tamás Bellák, Balázs Széky, János Farkas, Federica Lamberto, David Novak, Anita Fehér, Melinda Zana, and András Dinnyés. Establishment of human pluripotent stem cell-derived cortical neurosphere model to study pathomechanisms and chemical toxicity in kleefstra syndrome. Scientific Reports, Sep 2024. URL: https://doi.org/10.1038/s41598-024-72791-4, doi:10.1038/s41598-024-72791-4. This article has 3 citations and is from a peer-reviewed journal.
(wood2024theepigeneticnetwork pages 1-5): J Wood. The epigenetic network mediated by ehmt1 and its role in neurodevelopment disorders. Unknown journal, 2024.
(tzetis2025anovelframeshift pages 4-6): Maria Tzetis, Anastasios Mitrakos, Ioanna Papathanasiou, Vasiliki Koute, Konstantina Kosma, Roser Pons, Aspasia Michoula, Ioanna Grivea, and Aspasia Tsezou. A novel frameshift variant and a partial ehmt1 microdeletion in kleefstra syndrome 1 patients resulting in variable phenotypic severity and literature review. Genes, 16:521, Apr 2025. URL: https://doi.org/10.3390/genes16050521, doi:10.3390/genes16050521. This article has 0 citations.
(ren2024clinicalcharacteristicsand pages 12-12): Rong Ren, Yedan Liu, Peipei Liu, Jing Zhao, Mei Hou, Shuo Li, Zongbo Chen, and Aiyun Yuan. Clinical characteristics and genetic analysis of four pediatric patients with kleefstra syndrome. BMC Medical Genomics, Dec 2024. URL: https://doi.org/10.1186/s12920-024-02065-5, doi:10.1186/s12920-024-02065-5. This article has 4 citations and is from a peer-reviewed journal.
(barrero2024ehmt2lossoffunctionalterations pages 4-7): Maria Barrero, Beatriz Martínez-Delgado, Estrella López-Martín, Jennifer Kerkhof, Beatriz Baladron, Lidia Mielu, Diana Sanchez-Ponce, Ariadna Bada-Navarro, Marina Herrero Matesanz, Lidia Lopez-Jimenez, Jesica Rzasa, Dmitrijs Rots, Marta Fernandez-Prieto, Esther Hernandez-SanMiguel, Gema Gómez-Mariano, Purificacion Marin-Reina, Rosario Cazorla-Calleja, Javier Alonso, Tjitske Kleefstra, Manuel Posada, Eva Bermejo-Sánchez, and Bekim Sadikovic. Ehmt2 loss-of-function alterations cause a kleefstra-like syndrome. Unknown journal, Feb 2024. URL: https://doi.org/10.21203/rs.3.rs-3893528/v1, doi:10.21203/rs.3.rs-3893528/v1.
(morison2024expandingthephenotype pages 1-3): Lottie D. Morison, Milou G.P. Kennis, Dmitrijs Rots, Arianne Bouman, Joost Kummeling, Elizabeth Palmer, Adam P. Vogel, Frederique Liegeois, Amanda Brignell, Siddharth Srivastava, Zoe Frazier, Di Milnes, Himanshu Goel, David J. Amor, Ingrid E. Scheffer, Tjitske Kleefstra, and Angela T. Morgan. Expanding the phenotype of kleefstra syndrome: speech, language and cognition in 103 individuals. Journal of Medical Genetics, 61(6):578-585, Jan 2024. URL: https://doi.org/10.1136/jmg-2023-109702, doi:10.1136/jmg-2023-109702. This article has 21 citations and is from a domain leading peer-reviewed journal.
(roth2023histonelysinemethyltransferaserelated pages 7-9): Charlotte Roth, Helena Kilpinen, Manju A. Kurian, and Serena Barral. Histone lysine methyltransferase-related neurodevelopmental disorders: current knowledge and sarna future therapies. Frontiers in Cell and Developmental Biology, Feb 2023. URL: https://doi.org/10.3389/fcell.2023.1090046, doi:10.3389/fcell.2023.1090046. This article has 9 citations.
(morison2024expandingthephenotype pages 7-8): Lottie D. Morison, Milou G.P. Kennis, Dmitrijs Rots, Arianne Bouman, Joost Kummeling, Elizabeth Palmer, Adam P. Vogel, Frederique Liegeois, Amanda Brignell, Siddharth Srivastava, Zoe Frazier, Di Milnes, Himanshu Goel, David J. Amor, Ingrid E. Scheffer, Tjitske Kleefstra, and Angela T. Morgan. Expanding the phenotype of kleefstra syndrome: speech, language and cognition in 103 individuals. Journal of Medical Genetics, 61(6):578-585, Jan 2024. URL: https://doi.org/10.1136/jmg-2023-109702, doi:10.1136/jmg-2023-109702. This article has 21 citations and is from a domain leading peer-reviewed journal.
(morison2024expandingthephenotype pages 8-10): Lottie D. Morison, Milou G.P. Kennis, Dmitrijs Rots, Arianne Bouman, Joost Kummeling, Elizabeth Palmer, Adam P. Vogel, Frederique Liegeois, Amanda Brignell, Siddharth Srivastava, Zoe Frazier, Di Milnes, Himanshu Goel, David J. Amor, Ingrid E. Scheffer, Tjitske Kleefstra, and Angela T. Morgan. Expanding the phenotype of kleefstra syndrome: speech, language and cognition in 103 individuals. Journal of Medical Genetics, 61(6):578-585, Jan 2024. URL: https://doi.org/10.1136/jmg-2023-109702, doi:10.1136/jmg-2023-109702. This article has 21 citations and is from a domain leading peer-reviewed journal.
(roth2023histonelysinemethyltransferaserelated pages 6-7): Charlotte Roth, Helena Kilpinen, Manju A. Kurian, and Serena Barral. Histone lysine methyltransferase-related neurodevelopmental disorders: current knowledge and sarna future therapies. Frontiers in Cell and Developmental Biology, Feb 2023. URL: https://doi.org/10.3389/fcell.2023.1090046, doi:10.3389/fcell.2023.1090046. This article has 9 citations.
(roth2023histonelysinemethyltransferaserelated pages 2-3): Charlotte Roth, Helena Kilpinen, Manju A. Kurian, and Serena Barral. Histone lysine methyltransferase-related neurodevelopmental disorders: current knowledge and sarna future therapies. Frontiers in Cell and Developmental Biology, Feb 2023. URL: https://doi.org/10.3389/fcell.2023.1090046, doi:10.3389/fcell.2023.1090046. This article has 9 citations.

Ask OpenScientist

OpenScientist Report

Subtypes

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Treatments

Source YAML

References & Deep Research

Deep Research

Disease Pathophysiology Research Template

Target Disease

Research Objectives

Required Information

1. Core Pathophysiology

2. Key Molecular Players

3. Biological Processes (for GO annotation)

4. Cellular Components

5. Disease Progression

6. Phenotypic Manifestations

Citation Requirements

Output Format

Comprehensive Research Report: Kleefstra Syndrome Pathophysiology (EHMT1 haploinsufficiency)

0. Disease identifiers and scope

1) Key concepts and definitions (current understanding)

1.1 Core genetic and epigenetic mechanism

1.2 Pathophysiology as a “chromatinopathy” → circuit disorder

1.3 Molecular biomarker concept: DNA methylation episignature

2) Core pathophysiology: primary mechanisms, dysregulated pathways, cellular processes

2.1 Loss of H3K9me2 repression and specific promoter de-repression (GRIN1)

2.2 Neuronal network dysfunction and excitatory/inhibitory balance

2.3 REST/NRSF–miRNA axis: dysregulated neuronal gene repression and developmental timing

2.4 Synaptogenesis/connectivity deficits despite neurite overgrowth

2.5 Metabolic/oxidative stress vulnerability as a modifier mechanism

3) Key molecular players (genes/proteins, chemicals, cells, anatomy)

3.1 Genes/proteins (causal and mechanistic)

3.2 Chemical entities and small molecules relevant to mechanisms

3.3 Cell types (primary affected/implicated)

3.4 Anatomical systems and tissues

4) Biological processes and cellular components (GO-oriented)

5) Disease progression model (sequence of events)

6) Phenotypic manifestations and mechanistic links (with 2024 statistics)

7) Recent developments (2023–2024) and latest research themes

7.1 2024: Variant interpretation, genotype–mechanism insights, and episignatures

7.2 2024: Human 3D cortical neurosphere models for pathomechanisms and screening

7.3 2023: Therapeutic concept reviews for histone methyltransferase haploinsufficiency disorders

8) Current applications and real-world implementations

8.1 Clinical phenotyping and care

8.2 Molecular diagnostics: episignatures / EpiSign-style approaches

8.3 Disease modeling for mechanism and screening

9) Expert opinions and analysis (authoritative interpretations)

10) Evidence items (PMIDs) and priority references (with URLs and dates)

11) Limitations of this synthesis

Figures/tables used